Apellis Pharmaceuticals, Inc.
APLS
$22.07
$0.823.84%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.99M | -228.17M | -223.68M | -197.88M | -250.10M |
| Total Depreciation and Amortization | 1.68M | 1.80M | 1.80M | 1.80M | 1.83M |
| Total Amortization of Deferred Charges | 2.43M | 2.45M | 2.07M | 1.56M | 1.05M |
| Total Other Non-Cash Items | 109.07M | 108.36M | 115.97M | 125.01M | 131.39M |
| Change in Net Operating Assets | -79.30M | 120.06M | 95.54M | -18.36M | -89.26M |
| Cash from Operations | 78.86M | 4.49M | -8.29M | -87.87M | -205.10M |
| Capital Expenditure | -225.00K | -77.00K | -118.00K | -403.00K | -478.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 99.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -225.00K | -77.00K | -118.00K | -403.00K | -379.00K |
| Total Debt Issued | 0.00 | 0.00 | 365.45M | 365.45M | 365.45M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.28M | 11.04M | 9.63M | 18.83M | 44.28M |
| Repurchase of Common Stock | -26.00K | -36.00K | -36.00K | -57.00K | -44.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.63M | -5.63M | -333.75M | -234.98M | -260.36M |
| Cash from Financing | 3.63M | 5.37M | 41.30M | 149.24M | 149.33M |
| Foreign Exchange rate Adjustments | 101.00K | 252.00K | -91.00K | -659.00K | 890.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.36M | 10.04M | 32.80M | 60.31M | -55.26M |